Signalisation cellulaire et cancer pp 215-232 | Cite as
Les voies de contrôle de l’apoptose
Résumé
L’apoptose constitue une des modalités les plus importantes de mort cellulaire, si importante qu’elle a éclipsé toutes les autres que l’on commence seulement à redécouvrir. L’apoptose est une mort cellulaire programmée, active, mise en oeuvre en réponse à des signaux d’origine intracellulaire (lésions de l’ADN, anomalies de la mitose, stress oxydatif) ou extracellulaires (messages de mort provenant d’autres cellules) et aboutissant à l’activation de protéases capables d’hydrolyser les constituants cellulaires, les caspases. L’apoptose joue une multitude de rôles physiologiques fondamentaux lors de l’embryogenèse et dans l’homéostasie tissulaire: pour ne citer qu’un seul exemple, elle est responsable de l’involution du thymus lors du passage de l’enfance à l’âge adulte. On a fait de l’apoptose la voie de passage obligée de l’action des agents cytotoxiques, même si elle est souvent dans ce cas une conséquence phénotypique secondaire à des mécanismes d’actions ne la concernant qu’indirectement. On l’oppose souvent à la nécrose, alors que d’autres points d’opposition et de comparaison sont également à chercher du côté de la sénescence ou de la mort mitotique.
Preview
Unable to display preview. Download preview PDF.
Bibliographie
- Ashkenazi A. (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov; 7: 1001–12.PubMedCrossRefGoogle Scholar
- Ashkenazi A. (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer; 2: 420–30.PubMedCrossRefGoogle Scholar
- Bao Q, Shi Y. (2007) Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ; 14: 56–65.PubMedCrossRefGoogle Scholar
- Chipuk JE, Bouchier-Hayes L, Green DR. (2006) Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Diff; 13: 1396–402.CrossRefGoogle Scholar
- Chipuk JE, Green DR. (2008) How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol; 18: 157–64.PubMedCrossRefGoogle Scholar
- Cory S, Adams JM. (2002) The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer; 2: 647–56.PubMedCrossRefGoogle Scholar
- Dempsey PW, Doyle SE, He JQ, Cheng G. (2003) The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev; 14: 193–209.PubMedCrossRefGoogle Scholar
- Fesik SW. (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer; 5: 876–85.PubMedCrossRefGoogle Scholar
- Igney FH, Krammer PH. (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer; 2: 277–88.PubMedCrossRefGoogle Scholar
- Johnstone RW, Frew AJ, Smyth MJ. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer; 8: 782–98.PubMedCrossRefGoogle Scholar
- Kang MH, Reynolds CP. (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res; 15: 1126–32.PubMedCrossRefGoogle Scholar
- Kruyt FAE. (2008) TRAIL and cancer therapy. Cancer Lett; 263: 14–25.PubMedCrossRefGoogle Scholar
- LaCasse EC, Mahoney DJ, Cheung HH et al. (2008) IAP-targeted therapies for cancer. Oncogene; 27: 6252–75.PubMedCrossRefGoogle Scholar
- Lessene G, Czabotar PE, Colman P. (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov; 7: 989–1000.PubMedCrossRefGoogle Scholar
- Li J, Yuan J. (2008) Caspases in apoptosis and beyond. Oncogene; 27: 6194–206.PubMedCrossRefGoogle Scholar
- Mahalingam D, Szegezdi E, Keane M et al. (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev; 35: 280–8.PubMedCrossRefGoogle Scholar
- Marzo I, Naval J. (2008) Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol; 76: 939–46.PubMedCrossRefGoogle Scholar
- Okada H, Mak TW. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer; 4: 592–603.PubMedCrossRefGoogle Scholar
- Vogler M, Dinsdale D, Dyer MJ, Cohen GM. (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ; 16: 360–7.PubMedCrossRefGoogle Scholar
- Yip KW, Reed JC. (2008) Bcl-2 family proteins and cancer. Oncogene; 27: 6398–406.PubMedCrossRefGoogle Scholar
- Youle RJ, Strasser A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol; 9: 47–59.PubMedCrossRefGoogle Scholar
- Yu JW, Shi Y. (2008) FLIP and the death effector domain family. Oncogene; 27: 6216–27.PubMedCrossRefGoogle Scholar